Literature DB >> 8838721

Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.

J A Pérez-Molina, R López-Vélez, P Montilla, A Guerrero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8838721     DOI： 10.1097/00002030-199602000-00023

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases.

Authors:  C Agostoni; N Dorigoni; A Malfitano; L Caggese; G Marchetti; S Corona; S Gatti; M Scaglia
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Visceral leishmaniasis in patients infected with the human immunodeficiency virus.

Authors:  F Laguna; M Adrados; J Alvar; V Soriano; M E Valencia; V Moreno; R Polo; J Verdejo; M I Jiménez; P Martínez; M L Martínez; J M González-Lahoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

Review 4.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

5.  Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.

Authors:  Ermias Diro; Koert Ritmeijer; Marleen Boelaert; Fabiana Alves; Rezika Mohammed; Charles Abongomera; Raffaella Ravinetto; Maaike De Crop; Helina Fikre; Cherinet Adera; Robert Colebunders; Harry van Loen; Joris Menten; Lutgarde Lynen; Asrat Hailu; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2015-10-02

Review 6.  Therapeutic options for visceral leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 7.  Visceral leishmaniasis and HIV coinfection in the Mediterranean region.

Authors:  Begoña Monge-Maillo; Francesca F Norman; Israel Cruz; Jorge Alvar; Rogelio López-Vélez
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

8.  Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.

Authors:  Ermias Diro; Tansy Edwards; Koert Ritmeijer; Helina Fikre; Charles Abongomera; Aderajew Kibret; Clélia Bardonneau; Peninah Soipei; Brian Mutinda; Raymond Omollo; Johan van Griensven; Eduard E Zijlstra; Monique Wasunna; Fabiana Alves; Jorge Alvar; Asrat Hailu; Neal Alexander; Séverine Blesson
Journal:  PLoS Negl Trop Dis       Date:  2019-02-21

9.  Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.

Authors:  Ermias Diro; Koert Ritmeijer; Marleen Boelaert; Fabiana Alves; Rezika Mohammed; Charles Abongomera; Raffaella Ravinetto; Maaike De Crop; Helina Fikre; Cherinet Adera; Harry van Loen; Achilleas Tsoumanis; Wim Adriaensen; Asrat Hailu; Johan van Griensven
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.